AML patients with elevated FCN1 expression exhibited lower TIDE scores, indicative of enhanced efficacy and prolonged survival with ICB therapy, underscoring FCN1’s role in modulating tumor inflammation and immune responses by regulating immune cell infiltration, expression of immune regulatory factors, and tumor-associated immune activity. The gene discussed is FCN1; the disease is acute myeloid leukemia.